---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-082092"
form_type: "8-K"
ticker: "RKDA"
cik: "0001469443"
company_name: "Arcadia Biosciences, Inc."
filed_at: "2024-07-08T23:59:59+00:00"
generated_at: "2026-05-31T22:58:48.696420+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Arcadia CEO Stanley Jacot resigns; CFO Schaefer promoted to CEO, Kawakami named CFO

## Summary
- Stanley Jacot, Jr. resigned as president, CEO, and director on July 2, 2024; cash severance $288,077 + 12-month option acceleration + COBRA through Feb 2025.
- CFO Thomas J. Schaefer appointed president and CEO effective July 5, 2024; he had been CFO since Jan 2023.
- Mark Kawakami appointed CFO effective July 5, 2024; he was VP Finance since Jan 2023; base salary $212,063.
- Separation Agreement includes general release of claims, confidentiality, and non-disparagement by Jacot.

## SEC filing metadata
- accession: 0000950170-24-082092
- form_type: 8-K
- ticker: RKDA
- cik: 0001469443
- company_name: Arcadia Biosciences, Inc.
- filed_at: 2024-07-08T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1469443/000095017024082092/0000950170-24-082092-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1469443/000095017024082092/rkda-20240702.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-082092
- JSON: https://secwatch.observer/filing/0000950170-24-082092.json
- Plain text: https://secwatch.observer/filing/0000950170-24-082092.txt

## Key facts
- Executive change
  Stanley Jacot, Jr. resigned as president, chief executive officer and director at Arcadia Biosciences, Inc..
  - Action: resigned
  - Role: president, chief executive officer and director
  source text: Mr. Jacot resigned as Arcadia’s president, chief executive officer and director.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1469443/000095017024082092/0000950170-24-082092-index.htm
- Executive change
  Mark Kawakami was appointed as chief financial officer at Arcadia Biosciences, Inc..
  - Action: appointed
  - Role: chief financial officer
  source text: Arcadia’s board of directors appointed Mark Kawakami as Arcadia’s new chief financial officer to succeed Mr. Schaefer, effective as of July 5, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1469443/000095017024082092/0000950170-24-082092-index.htm
- Executive change
  Thomas J. Schaefer was appointed as president and chief executive officer at Arcadia Biosciences, Inc..
  - Action: appointed
  - Role: president and chief executive officer
  source text: Arcadia’s board of directors appointed Thomas J. Schaefer, Arcadia’s current chief financial officer, to the position of president and chief executive officer of Arcadia, effective as of July 5, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1469443/000095017024082092/0000950170-24-082092-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.